糖尿病眼病的诊断、治疗及监测（2023年更新）
[Diagnosis, treatment and monitoring of diabetic eye disease (Update 2023)].
作者信息
Pollreisz Andreas, Gasser-Steiner Vanessa, Gerendas Bianca, Mennel Stefan, Radda Stephan, Sacu Stefan, Scholda Christoph, Stolba Ulrike, Wedrich Andreas
机构信息
Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Augenärztliche Ordination Gasser-Steiner, Weiz, Österreich.
出版信息
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):195-200. doi: 10.1007/s00508-022-02119-7. Epub 2023 Apr 20.
Abstract
Diabetes mellitus can cause diabetic retinopathy, diabetic macular edema, optic neuropathy, cataract or dysfunction of the eye muscles. The incidence of these disorders correlates with disease duration and quality of metabolic control. Regular ophthalmological examinations are needed to prevent sight-threatening advanced stages of diabetic eye diseases.
摘要
糖尿病可导致糖尿病性视网膜病变、糖尿病性黄斑水肿、视神经病变、白内障或眼肌功能障碍。这些病症的发病率与病程和代谢控制质量相关。需要定期进行眼科检查以预防威胁视力的糖尿病眼病晚期。
相似文献
1
[Diagnosis, treatment and monitoring of diabetic eye disease (Update 2023)].糖尿病眼病的诊断、治疗及监测（2023年更新）
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):195-200. doi: 10.1007/s00508-022-02119-7. Epub 2023 Apr 20.
2
[Diagnosis, treatment and monitoring of diabetic eye disease (Update 2019)].糖尿病眼病的诊断、治疗及监测（2019年更新版）
Wien Klin Wochenschr. 2019 May;131(Suppl 1):164-168. doi: 10.1007/s00508-019-1445-1.
3
[Diagnosis, treatment and monitoring of diabetic eye control].糖尿病眼部控制的诊断、治疗与监测
Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S97-102. doi: 10.1007/s00508-016-0983-z.
4
Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.糖尿病性黄斑水肿的治疗：在治疗糖尿病眼病所致视力损害方面实现最佳患者管理
Eye (Lond). 2017 May;31(S1):S1-S20. doi: 10.1038/eye.2017.53.
5
Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.《糖尿病性黄斑水肿管理的第一议定书实用经验》
Dev Ophthalmol. 2017;60:91-108. doi: 10.1159/000459692. Epub 2017 Apr 20.
6
[Diabetic eye disease].[糖尿病眼病]
Ther Umsch. 2009 Mar;66(3):183-8. doi: 10.1024/0040-5930.66.3.183.
7
[Eye complications in type 2 diabetes mellitus].[2型糖尿病的眼部并发症]
Ugeskr Laeger. 2012 Sep 10;174(37):2147-50.
8
A spreadsheet template for the analysis of optical coherence tomography in the longitudinal management of diabetic macular edema.用于糖尿病性黄斑水肿纵向管理中光学相干断层扫描分析的电子表格模板。
Ophthalmic Surg Lasers Imaging. 2006 Sep-Oct;37(5):399-405. doi: 10.3928/15428877-20060901-07.
9
Diabetic eye disease: A review of screening and management recommendations.糖尿病眼病：筛查和管理建议综述。
Clin Exp Ophthalmol. 2021 Mar;49(2):128-145. doi: 10.1111/ceo.13894. Epub 2021 Jan 10.
10
Management of diabetic macular edema in Japan: a review and expert opinion.日本糖尿病性黄斑水肿的管理：综述与专家意见
Jpn J Ophthalmol. 2018 Jan;62(1):1-23. doi: 10.1007/s10384-017-0537-6. Epub 2017 Dec 5.
引用本文的文献
1
Risk factors for pupil changes in patients with diabetic retinopathy and cataract after phacoemulsification with intraocular lens implantation.糖尿病视网膜病变和白内障患者白内障超声乳化人工晶状体植入术后瞳孔变化的危险因素。
BMC Ophthalmol. 2025 Apr 28;25(1):252. doi: 10.1186/s12886-025-04080-1.
2
Artificial intelligence in managing retinal disease-current concepts and relevant aspects for health care providers.人工智能在视网膜疾病管理中的应用——医疗服务提供者的当前概念及相关方面
Wien Med Wochenschr. 2025 May;175(7-8):143-152. doi: 10.1007/s10354-024-01069-1. Epub 2025 Feb 24.
本文引用的文献
1
Imaging diabetic retinal disease: clinical imaging requirements.糖尿病视网膜病变的影像学检查：临床影像学要求
Acta Ophthalmol. 2022 Nov;100(7):752-762. doi: 10.1111/aos.15110. Epub 2022 Feb 9.
2
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.在糖尿病性黄斑水肿（YOSEMITE 和 RHINE）患者中，每 16 周进行一次玻璃体腔内 faricimab 延长给药的疗效、持久性和安全性：两项随机、双盲、3 期试验。
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
3
Optical Coherence Tomography Angiography in Diabetic Patients: A Systematic Review.糖尿病患者的光学相干断层扫描血管造影：一项系统评价
Biomedicines. 2021 Dec 31;10(1):88. doi: 10.3390/biomedicines10010088.
4
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.雀鹰和风筝研究：布罗鲁单抗治疗糖尿病性黄斑水肿两项III期关键试验的52周结果
Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14.
5
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.视力、玻璃体积血及其他眼部结局：玻璃体切割术与阿柏西普治疗糖尿病视网膜病变玻璃体积血的比较：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2021 Jul 1;139(7):725-733. doi: 10.1001/jamaophthalmol.2021.1110.
6
Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.玻璃体腔内抗血管内皮生长因子与假治疗预防糖尿病视网膜病变致盲性并发症的效果：方案 W 随机临床试验。
JAMA Ophthalmol. 2021 Jul 1;139(7):701-712. doi: 10.1001/jamaophthalmol.2021.0606.
7
Diabetic Retinopathy and Maculopathy.糖尿病视网膜病变和黄斑病变。
Exp Clin Endocrinol Diabetes. 2021 Aug;129(S 01):S64-S69. doi: 10.1055/a-1284-6223. Epub 2020 Dec 17.
8
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.玻璃体积血患者增生性糖尿病视网膜病变中玻璃体内注射阿柏西普与全视网膜光凝联合玻璃体切除术对视力的影响：一项随机临床试验。
JAMA. 2020 Dec 15;324(23):2383-2395. doi: 10.1001/jama.2020.23027.
9
Association of macular perfusion status with microvascular parameters up to the far periphery in diabetic retinopathy using multimodal imaging.利用多模态成像技术研究糖尿病视网膜病变中黄斑灌注状态与直至远周边部的微血管参数之间的关联。
Int J Retina Vitreous. 2020 Nov 4;6(1):50. doi: 10.1186/s40942-020-00253-w.
10
[Not Available].[无可用内容]。
Klin Monbl Augenheilkd. 2020 Aug;237(8):990-994. doi: 10.1055/a-1191-1395. Epub 2020 Jul 16.
Zotero 插件